Clear cell renal cell carcinoma represents one of the most common and lethal subtypes of kidney cancer, characterized by distinct molecular features that drive both tumor progression and treatment response. The hallmark genetic alteration in ccRCC is the loss of the VHL tumor suppressor gene, which occurs in the majority of cases and leads to constitutive activation of hypoxia-inducible factors. However, recent comprehensive genomic analyses have revealed a complex landscape of additional mutations that profoundly influence disease biology and therapeutic susceptibility.

Among the most significant discoveries in ccRCC genomics are recurrent mutations in chromatin remodeling genes, particularly PBRM1, BAP1, and SETD2. These genes encode proteins that modify chromatin structure and regulate gene expression through histone modifications and DNA methylation. PBRM1, which encodes a subunit of the SWI/SNF chromatin remodeling complex, is mutated in approximately 40% of ccRCC cases. BAP1, a deubiquitinase involved in chromatin regulation and DNA damage response, is mutated in about 15% of cases and is associated with aggressive disease and poor prognosis.

The functional consequences of these chromatin remodeling mutations extend beyond epigenetic dysregulation. Emerging evidence suggests that defects in these genes impair DNA damage repair pathways, rendering tumor cells vulnerable to specific therapeutic interventions. This phenomenon, known as synthetic lethality, has been successfully exploited in other cancer types and holds promise for ccRCC treatment.

Importantly, the genetic landscape of ccRCC also shapes the tumor immune microenvironment. Tumors with different driver mutations exhibit distinct patterns of immune cell infiltration, cytokine expression, and checkpoint molecule presentation. For instance, PBRM1-deficient tumors tend to have enhanced immune cell infiltration and may respond differently to immune checkpoint inhibitors compared to BAP1-mutant tumors. This observation provides a mechanistic basis for the variable responses to immunotherapy observed in ccRCC patients.

The integration of genomic and immunologic profiling in ccRCC has revealed additional layers of complexity. Tumors with high mutational burden, often associated with DNA repair defects, may generate more neoantigens and thus be more susceptible to immune recognition. Conversely, defects in antigen presentation machinery can enable immune evasion despite high neoantigen loads. Understanding these interactions is critical for optimizing treatment selection and developing rational combination therapies.

Therapeutic implications of these insights are already being explored in clinical trials. Combination strategies pairing DNA damage response inhibitors with immune checkpoint blockade represent a promising approach based on the premise that enhancing genomic instability may increase tumor immunogenicity. Additionally, patient selection based on mutational status may improve response rates and minimize unnecessary toxicity.

Future directions in ccRCC research include further characterization of the functional consequences of specific mutations, development of biomarkers to predict treatment response, and exploration of novel therapeutic targets arising from genetic vulnerabilities. The continued integration of genomic, epigenomic, and immunologic data promises to refine our understanding of ccRCC biology and improve outcomes for patients with this challenging disease.

DOI
10.1007/s11684-025-1136-4